Medicinal chemistry & drug design
POSTDOCTORAL RESEARCHERS
- Leticia Manen Freixa
PREDOCTORAL RESEARCHERS
- Luca Ruvo
SCIENTIFIC SUPPORT
- Santiago Santos Gil
Cancer
Oncobell
Scientific production
2
PAPERS
Average IF: 30,00
2 PUBLICATIONS IN FIRST DECILE
2 PUBLICATIONS IN FIRST QUARTILE
1 PUBLICATION IN OPEN ACCESS
Selected publications
- Edwards,AM;Owen,DR;Structural Genomics Consortium Target Working Group,2035, Protein-ligand data at scale to support machine learning., Nat. Rev. Chem., 2025;9(9):634-645, doi:10.1038/s41570-025-00737-z
- Boni,J;Fernández González,M;Han,H;Roca,C;Wong,CJ;Rioja,C;Nogué,C et al, Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors., EMBO J, 2025;44(24):7513-7540, doi:10.1038/s44318-025-00600-3
Research highlights
PROJECTS
3 Ongoing competitive projects
1 Ongoing non competitive project
NETWORKS
Chemical Probes Portal
canSAR
Target 2035
MAINFRAME
Selected projects
- CP22/00122_Madre. CONTRATOS MIGUEL SERVET . Instituto de Salud Carlos III (ISCIII). Budget: 308.600€. 2023-2028. PI: ALBERT ANTOLIN HERNANDEZ.
- PID2022-136344OA-I00. Caracterización de metabolitos de farmacos usando biologia de sistemas para su explotación en medicina de precisión (META-PRIME).. Ministerio de Ciencia e Innovación. Budget: 162.500€. 2023-2026. PI: ALBERT ANTOLIN HERNANDEZ.
- Co-discovery of Multi-Target Molecules for Precision Oncology in colorectal cancer. THE INSTITUTE OF CANCER RESEARCH. Budget: 50.000€. 2023-2025. PI: ALBERT ANTOLIN HERNANDEZ.
- Multi-Target Molecules for Precision Oncology in colorectal. VIVAN Therapeutics. Budget: 50.000€. 2023-2025. PI: ANTOLIN HERNANDEZ, ALBERT.